Genkyotex : Ajustement objectif de cours post regroupement d’actions
>Regroupement d’actions par 10 - Nous mettons à jour notre modèle suite à l’annonce il y a quelques jours de la finalisation du regroupement d’actions par 10. Ceci n’a aucun impact sur notre valorisation, les actionnaires ayant 10 actions se retrouvent donc avec une seule action dont la valeur augmente d’autant. Notre objectif de cours de cours passe donc de 1 € à 10 €.GKT831 : Publication imminente des résultats finaux P2 PBC - Le 11 mars dernier, l...Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.